# Ascendis Pharma Oncology Division A/S: Phase 2 study closed enrollment, 320 enrolled (Advanced Solid Tumor, Locally Advanced Solid Tumor)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Ascendis Pharma Oncology Division A/S |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies |
| NCT ID | NCT05081609 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Platinum-resistant Ovarian Cancer; Post Anti-PD-1 Melanoma; 2L+ Cervical Cancer |
| Intervention types | drug, procedure |
| Target enrollment | 320 |
| Site countries | United States, Australia, Belgium, Canada, Italy, Poland, Singapore, South Korea, Spain, Taiwan |
| Posted | 2021-10-18 |
| Planned start | 2022-01-11 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-13 |
| Last update posted | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 320 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05081609). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.